Abstract
Prognostic factors can guide the physician in selecting the optimal treatment for an individual patient. This study investigates the prognostic value of erythropoietin (EPO) and EPO receptor (EPO-R) expression of tumor cells for locoregional control and survival in non-small-cell lung cancer (NSCLC) patients. Fourteen factors were investigated in 62 patients irradiated for stage II/III NSCLC, as follows: age, gender, Karnofsky performance score (KPS), histology, grading, TNM/American Joint Committee on Cancer (AJCC) stage, surgery, chemotherapy, pack years (average number of packages of cigarettes smoked per day multiplied by the number of years smoked), smoking during radiotherapy, hemoglobin levels during radiotherapy, EPO expression, and EPO-R expression. Additionally, patients with tumors expressing both EPO and EPO-R were compared to those expressing either EPO or EPO-R and to those expressing neither EPO nor EPO-R. On univariate analysis, improved locoregional control was associated with AJCC stage II cancer (p < 0.048), surgery (p < 0.042), no smoking during radiotherapy (p = 0.024), and no EPO expression (p = 0.001). A trend was observed for a KPS of >70 (p = 0.08), an N stage of 0 to 1 (p = 0.07), and no EPO-R expressi...Continue Reading
References
Nov 1, 1985·Archives of Environmental Health·C BorlandT Higenbottam
Nov 14, 1980·JAMA : the Journal of the American Medical Association·A Johnston-EarlyR Makuch
Nov 1, 1982·International Journal of Radiation Oncology, Biology, Physics·G W Barendsen
Jan 21, 1993·The New England Journal of Medicine·G P BrowmanM N Levine
Jun 12, 1999·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M BernaudinE Petit
Sep 25, 1999·Growth Factors·P A Tilbrook, S P Klinken
Dec 11, 1999·Cancer·N FleshnerP Russo
Sep 5, 2002·Cancer·Geza AcsAjay Verma
Dec 20, 2002·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Peter VaupelMichael Höckel
May 22, 2003·The American Journal of Pathology·Geza AcsAjay Verma
Jan 14, 2004·Chest·C Martin TammemagiPaul Kvale
Feb 28, 2004·The British Journal of Radiology·H-C HsuL-M Sun
Apr 6, 2004·Molecular and Cellular Endocrinology·Takafumi YamazakiMasato Fujisawa
May 26, 2004·Cancer·Geza AcsAjay Verma
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew E HardeeMark W Dewhirst
May 10, 2006·International Journal of Radiation Oncology, Biology, Physics·Branislav JeremićSlobodan Milisavljević
May 16, 2006·Journal of Endocrinological Investigation·C M YatesG L Francis
Oct 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael HenkeFrank Pajonk
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pierre SaintignyJean-Charles Soria
Oct 31, 2007·International Journal of Radiation Oncology, Biology, Physics·Dirk RadesErgin Kilic
Feb 9, 2008·International Journal of Radiation Oncology, Biology, Physics·Dirk RadesJuergen Dunst
Citations
Aug 11, 2011·PloS One·Thilo WelschNathalia A Giese
Mar 1, 2012·PloS One·Lisandra WestRavi Salgia
Oct 25, 2013·PloS One·Anita RózsásJózsef Tóvári
Aug 1, 2012·Biologics : Targets & Therapy·Steve Elliott, Angus M Sinclair
May 24, 2013·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·N D SeiboldD Rades
Jun 26, 2015·Cancer Medicine·Steven E SchildJeff A Sloan
Nov 27, 2014·Frontiers in Immunology·Nataša DebeljakArthur J Sytkowski
Oct 23, 2016·Clinical Lung Cancer·Dirk RadesStefan Janssen
Nov 16, 2017·Oncotarget·Lei HeQiuyang Zhang
May 10, 2019·BMC Cancer·Rafał SuwinskiDorota Butkiewicz
Jan 20, 2021·Expert Opinion on Drug Metabolism & Toxicology·Yi ZhengPei Cai